Sign in

    Jade Montgomery

    Consultant Research Analyst at H.C. Wainwright

    Jade Montgomery is a Consultant Research Analyst at H.C. Wainwright & Co., LLC, specializing in equity research primarily within the healthcare and biotech sectors. Dr. Montgomery has covered companies such as Biocept Inc. and Spruce Biosciences Inc., contributing analysis and industry insights at major conferences; performance data such as success rates or platform rankings are not publicly available. With over thirteen years of experience, Montgomery has held roles as a Behavior Technician at Balance Autism, Clinical Coordinator at Southwest Network, and joined H.C. Wainwright in a research analyst capacity. Professional credentials include a doctoral degree and an established track record as a specialist at investment conferences, though securities licenses or FINRA registration details are not public.

    Jade Montgomery's questions to Sensus Healthcare (SRTS) leadership

    Jade Montgomery's questions to Sensus Healthcare (SRTS) leadership • Q3 2024

    Question

    Asked about 2025 targets for system shipments and Fair Deal agreements, the financial impact of the Platinum deal on Q4, and the sales outlook for Q4 compared to the prior year.

    Answer

    The company does not provide specific guidance but aims for maximum growth. The Platinum deal is a recurring revenue model and will not be booked as a large sale in Q4; its revenue will build over time and become significant in the second half of 2025. The company will continue to pursue direct sales and leasing arrangements alongside these agreements.

    Ask Fintool Equity Research AI